Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG9924 plus methotrexate in anti-TNF inadequate responder rheumatoid arthritis
2006-005467-26Phase 2Terminated
- Sponsor
- Biogen
- Start
- Jan 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing BG9924 + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: ACR50 response at Week 14. Started Jan 2007; status: terminated.
02
Drugs
baminercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-005467-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005467-26.